

# MATILDA

MAGicTouch Intervention Leap for Dialysis Access Trial

An Investigator Initiated prospective pilot study to assess the safety and efficacy of MagicTouch AVF in Dysfunctional AVF




## COMPLEX PATIENT COHORT

<b>Hypertension</b>	<b>Hyperlipidaemia</b>	<b>Diabetes Mellitus</b>	<b>Juxta-Anastomotic Segments</b>
97%	90.9%	63.6%	40.4%

PRINCIPAL INVESTIGATOR: PROF TJUN TANG


## Clinical Outcome\*

### Patency 12 & 24 Outcome



<b>Technical Success</b>	<b>Procedural Success</b>
100%	100%
<b>Impressive Target Lesion Primary Patency (3 &amp; 6 Months)</b>	
93.9% & 82.9%	

### Comparison



## Key Takeaways

MATILDA demonstrates that using MagicTouch AVF for angioplasty of dysfunctional AVF is safe, with no significant adverse events and complete technical as well as clinical success. The trial reports excellent outcomes at 1 year, showing it to be a viable and effective treatment option. Results also appear better compared to other studies with Sirolimus

\*Article published in Eur J Vasc Endovasc Surg: <https://doi.org/10.1016/j.ejvs.2021.04.014> | Presented in LINC2022 by Tjun TANG.

